CoChat

Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review.

Open access
Orme, Michelle E, Voreck, Anja, Aksouh, Redha, Schreurs, Marco W J · 2022 · The Journal of Applied Laboratory Medicine

The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index; 15 of the 37 sources its claims cite were checked for support.

Abstract

Anti-dsDNA testing shows considerable variation in test specificity, with potential impact on the management of SLE patients. This systematic review identified studies reporting anti-dsDNA test accuracy in SLE. A meta-analysis was conducted to estimate specificity by test method. CLIFT and fluorescence enzyme immunoassay methods are likely to be >= 90% specific. CLIFT specificity was estimated at 98.7% (95% CI 96.7%-99.5%) based on 8 studies/7 tests, while Euroimmun specificity was 97.8% and EliA specificity was 94.7%. Specificities of other quantitative methods were not fully demonstrated to be >= 90%.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 30 studies covering 43 anti-dsDNA tests found considerable variation in specificity for SLE, with some tests likely exceeding 90% specificity and others not demonstrated to do so. The authors conclude that test choice and interpretation should account for method, named test, and the relevance of the control group.

Key findings

  • Across 30 studies and 66 result sets for 43 anti-dsDNA tests, some studies reported false-positive rates above 10%: 2 CLIA, 2 NOVA Lite CLIFT, 4 ELISA, 3 Farr-RIA, and 3 MIA studies.
  • Pooled specificity estimates were: Euroimmun CLIFT 97.8% (95% CI 96.2%–98.7%), 4 studies; EliA FEIA 94.7% (95% CI 91.7%–96.7%), 6 studies; CLIFT overall 98.7% (95% CI 96.7%–99.5%), 8 studies/7 tests.
  • Other estimates were: NOVA Lite CLIFT 96.0% (95% CI 87.2%–98.9%), 5 studies; CLIA 92.3% (95% CI 83.6%–96.6%), 6 studies/4 tests; MIA 89.3% (95% CI 86.1%–91.8%), 4 studies/2 tests; Farr-RIA 93.8% (95% CI 85.4%–97.5%), 11 studies/9 tests; ELISA 93.4% (95% CI 89.9%–95.7%), 15 studies/16 tests.
  • FEIA EliA and some CLIFT tests were likely to have >90% specificity and were assessed against relevant disease controls; for other methods, specificity was not fully demonstrated to be >90% and/or control groups included healthy patients, possibly overestimating specificity.

Methods

  • Systematic review of MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Database of Abstracts of Reviews of Effects, including cross-sectional or case-control diagnostic accuracy studies published January 2004 to August 2019, with at least 10 patients, an SLE cohort, a non-SLE control group, accepted SLE classification criteria (ACR 1982, ACR 1997, or SLICC 2012), and commercially available anti-dsDNA tests at manufacturer-recommended thresholds.
  • Thirty studies were included, yielding 66 sets of results for 43 different anti-dsDNA tests; study quality was assessed with QUADAS-2.
  • Specificity was calculated with exact (Clopper-Pearson) 95% CIs, and hierarchical summary ROC meta-analysis was conducted by test method or named test where feasible; when studies reported healthy and diseased controls separately, specificity was based on disease controls only.

Limitations

  • The paper states that most included studies were conducted in secondary/tertiary care settings and mostly European countries, which may limit generalization to primary care; the review was not designed to assess sensitivity; and too few data were available for individual tests within CLIA, MIA, Farr-RIA, and ELISA.
  • The paper states that 90% of studies used a case-control design, that some studies included healthy controls or non-representative disease controls, and that this may overestimate specificity; one CLIFT NOVA Lite result of 44% was excluded as an outlier.
  • The text makes evident potential conflict of interest: several authors report employment, stock ownership, personal fees, or grants from Thermo Fisher Scientific, and the review includes the EliA FEIA test from that company.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/jalm/jfab146

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

10 Valid · 1 Not valid · 8 Not checked · 92 Own results and interpretations

52 more claims · 2 with their cited sources checked

Create a free account to see all 111 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 39
  • Probably not a substantial claim. 23
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 74 references

Research works printed but not linked: 3

  1. Conrad, 2015, Autoantibodies in systemic autoimmune diseases., 73
  2. Macaskill, 2010, Handbook for systematic reviews of diagnostic test accuracy version 10
  3. Lopez-Hoyos, 2004, Clinical utility of antibodies to double-stranded DNA by a new immunofluorescence test, Lupus, 13, 144

Cited by

See all 30

Metadata

Authors
Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J.
Affiliations
  • ICERA Consulting Ltd, Swindon, UK
  • Thermo Fisher Scientific (Sweden) (SE)
  • Erasmus MC (NL)
Corresponding author
Orme, Michelle E
Venue
The Journal of Applied Laboratory Medicine
Published
2022-01-01
Volume
7
Issue
1
Pages
221-239
ISSN
  • 2475-7241 (ISSN-L)
  • 2576-9456
OpenAlex
W4206109719
Cited by
30
References
75
Citations by year
2026: 10 · 2025: 11 · 2024: 3 · 2023: 6
FWCI
0.37
Type
journal article
Language
en
Open access
Locations
  • The Journal of Applied Laboratory Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
Funders
Thermo Fisher Scientific
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
anti-dsDNA antibodies, systemic lupus erythematosus, diagnostic specificity, false positives, autoantibody detection, indirect immunofluorescence, fluorescence enzyme immunoassay, chemiluminescence immunoassay, multiplex immunoassay
MeSH terms
Autoantibodies, Cross-Sectional Studies, DNA, Fluorescent Antibody Technique, Humans, Lupus Erythematosus, Systemic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review. https://app.cochat.ai/papers/10.1093/jalm/jfab146
The paper
Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J. (2022). Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfab146

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.